Transdermal estrogen for female stress urinary incontinence in postmenopause

Objective: To evaluate the effect of transdermal estrogen for stress urinary incontinence in postmenopause. Study design: An open within patient, dose-finding study with transdermal 17-β-estradiol combined with cyclic medroxyprogesterone acetate was conducted over 9 months in 21 patients (mean age 57.3 years) suffering from urodynamically verified mild to moderate stress incontinence without detrusor instability. Results: Subjective improvement was noted in 16 out of 21 patients (76%). The dose level of 50 μg was better tolerated than 100 μg and sufficient enough to achieve continence. Conclusion: Transdermal estrogen therapy plays an adjuvant role in conservative therapy for mild to moderate stress urinary incontinence in postmenopausal women.